Safety and Efficacy Study of PRV111 and PRV211 in Subjects With Oral Squamous Cell Carcinoma

NCT ID: NCT05893888

Last Updated: 2025-06-15

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-11-07
• Study Completion Date: 2027-05-31

Brief Summary

Arm 1 ( Phase 2/3 Run in ):

PRV111: Topical Locoregional Delivery Placed Over the Tumor Region Primary Endpoint: Overall Response Rate (ORR) Primary Objective: Demonstrate the safety and efficacy of PRV111 in patients with Carcinoma in Situ (CIS) (WHO 2017)

Arm 2 (Phase 1) PRV211: Intraoperative Locoregional Delivery Placed into the Resected Tumor Bed Primary Endpoint: Safety Primary Objective: Determine Safety of PRV211 in intraoperative setting

Subject Assignment: Subjects will be assigned to Arm 1 or Arm 2 of this study based on disease staging Arm 1: Pathologically proven and clinically confirmed Tis/CIS of the lip or oral cavity Arm 2: Pathologically proven and clinically confirmed T1-T3, Nx, M0 of the lip or oral cavity

Detailed Description

Privo's PRV111 & PRV211 Product Description:

PRV111 (Cisplatin Transmucosal System) is a thin, 2-layer, matrix-type, transmucosal patch consisting of a chitosan matrix layer embedded with cisplatin loaded chitosan particles (CLPs) and a non-woven fabric adhesive unidirectional backing, which is applied to the matrix layer during manufacturing. The patch is self-adhesive.

In addition to the PRV111 patch, a separately packaged Permeation Enhancer (PE) Powder for Reconstitution is used in conjunction with PRV111. The reconstituted PE Solution is intended to improve the absorption of the cisplatin active ingredient and will be applied prior to patch application.

PRV211 is a nanoengineered delivery system intended for intraoperative chemotherapy treatment for all solid tumor surgeries immediately following surgical excision. The goal is to treat the tumor bed locally, eliminating any remaining micrometastases or close margins that are unable to be fully resected while avoiding system circulation.

ARM 1 Study Details PRV111 Topical Treatment

Screening: A screening period of up to 7 days is needed to evaluate subject eligibility for study participation. All subjects will undergo a baseline histopathological assessment at screening (confirming CIS of the oral cavity for inclusion), if an existing diagnosis does not exist. Also at screening, the investigator will determine if the patient requires surgery, and will assess the rest of the inclusion/exclusion criteria to check for eligibility.

Dose limiting Toxicity (DLT): DLT is defined as a clinically significant treatment-emergent AE (TEAE) or laboratory abnormality unrelated to surgery and/or disease progression, concurrent illness, or concomitant therapy within 1-month post-surgery Note: The dosing of 1.5 mg/cm2 per visit in this protocol is comparable to the one used in the prior completed phase 1/2 CLN-001 study, which has shown safety and efficacy causing no dose limiting toxicities (DLTs), related severe adverse events (SAEs) or systemic side effects.

Photo documentation: Tumors will be photographed including anatomic landmarks at each visit, prior to treatment at treatment visits for the ability to compare between visits. Photos are also required for documenting the location of biopsies taken. Additional details are provided in the Lab Manual.

Minimum Required Treatments for Efficacy Assessment: For assessing efficacy, each subject must complete at least 3 treatment visits.

Assessment for Postponement of Surgery: Response Assessment Criteria: If disease is not improved compared to baseline biopsy, subject proceeds to scheduled surgery, otherwise the subject will continue on with the PRV111 treatment regimen.

ARM 2 Study Details PRV211 Intraoperative Treatment

Screening: A screening period of up to 7 days is needed to evaluate subject eligibility for study participation. All subjects will be screened based on the SOC biopsy to obtain baseline histopathology. This biopsy will confirm the stage of the disease to be T1-T3, Nx, M0 of the oral cavity, amenable to surgery. Based on this confirmation, the rest of the inclusion/exclusion criteria will be checked for eligibility.

Safety and Efficacy of PRV211 Treatment: The safety of PRV211 treatment will be determined in the Safety Run-in study described below. Once the safety is determined, a second expansion study can be initiated in another study. The efficacy of PRV211 is determined in the expansion study. This efficacy will be assessed by the incidence of locoregional recurrence at 12 months.

Initial Safety Lead-in Study: This is an open label, safety lead-in phase 1b dose confirmation study in patients with T1-T3, Nx, M0 oral cancer, followed by an expansion phase 2 single arm study as an intraoperative chemotherapy with PRV211. For the purpose of safety detection, if greater than 33% of subjects being evaluated for safety present with dose-limiting toxicities (DLTs), the study is deemed unsafe.

For the Safety Lead-in Study, 3 subjects will be initially enrolled. If more than 1 subject has dose limiting toxicity (DLT), the study stops. Otherwise, 3 additional subjects will be enrolled and if more than 2 DLTs are detected in the total of 6 subjects, the study is deemed unsafe and the study stops. If 2 or less DLTs are observed, the treatment will be considered safe.

At the conclusion of the Safety Lead-in portion (6 patients), if PRV211 is determined to be safe, an expansion study can be initiated. The 6 subjects from the Safety Lead-in study will be included in the expansion study and these patients will be monitored for efficacy.

Conditions

Oral Squamous Cell Carcinoma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Arm 1: Pathologically proven and clinically confirmed Tis/CIS of the lip or oral cavity

PRV111 Topical Locoregional Delivery Placed Over the Tumor Region Primary Endpoint: Overall Response Rate (ORR) Primary Objective: Demonstrate the safety and efficacy of PRV111 in patients with Carcinoma in Situ (CIS) (WHO 2017)

Group Type: EXPERIMENTAL

PRV111 (Cisplatin Transmucosal System)

Intervention Type: DRUG

PRV111 (Cisplatin Transmucosal System) is a thin, 2-layer, matrix-type, transmucosal patch consisting of a chitosan matrix layer embedded with cisplatin loaded chitosan particles (CLPs) and a non-woven fabric adhesive unidirectional backing, which is applied to the matrix layer during manufacturing. The patch is self-adhesive. In addition to the PRV111 patch, a separately packaged Permeation Enhancer (PE) Powder for Reconstitution used in conjunction with PRV111. The reconstituted PE Solution is intended to improve the absorption of the cisplatin active ingredient and will be applied prior to patch application.

Arm 2: Pathologically proven and clinically confirmed T1-T3, Nx, M0 of the lip or oral cavity

Arm 2 PRV211 Intraoperative Locoregional Delivery Placed into the Resected Tumor Bed Primary Endpoint: Safety Primary Objective: Determine Safety of PRV211 in intraoperative setting

Group Type: EXPERIMENTAL

PRV211 (Intraoperative Cisplatin System)

Intervention Type: DRUG

PRV211 system is comprised of two parts, a liquid permeation enhancer (PE) and cisplatin patch. The permeation is brushed onto the resected tumor bed and after 5 minutes the patch can be applied directly over the same area. Apply up to 2 layers of the PRV211 system to the tumor bed post-resection. The duration of the PRV211 treatment takes approximately 10-20 minutes and then the surgeon can continue as planned with the rest of the standard of care procedure. The proposed starting dose is 0.5 mg/cm2 of cisplatin on the tumor bed. This approach can be safe and effective in preventing locoregional recurrence after surgery and eliminating high-risk factors for local recurrence, such as dysplasia at the margins.

Interventions

PRV211 (Intraoperative Cisplatin System)

PRV211 system is comprised of two parts, a liquid permeation enhancer (PE) and cisplatin patch. The permeation is brushed onto the resected tumor bed and after 5 minutes the patch can be applied directly over the same area. Apply up to 2 layers of the PRV211 system to the tumor bed post-resection. The duration of the PRV211 treatment takes approximately 10-20 minutes and then the surgeon can continue as planned with the rest of the standard of care procedure. The proposed starting dose is 0.5 mg/cm2 of cisplatin on the tumor bed. This approach can be safe and effective in preventing locoregional recurrence after surgery and eliminating high-risk factors for local recurrence, such as dysplasia at the margins.

Intervention Type: DRUG

PRV111 (Cisplatin Transmucosal System)

PRV111 (Cisplatin Transmucosal System) is a thin, 2-layer, matrix-type, transmucosal patch consisting of a chitosan matrix layer embedded with cisplatin loaded chitosan particles (CLPs) and a non-woven fabric adhesive unidirectional backing, which is applied to the matrix layer during manufacturing. The patch is self-adhesive. In addition to the PRV111 patch, a separately packaged Permeation Enhancer (PE) Powder for Reconstitution used in conjunction with PRV111. The reconstituted PE Solution is intended to improve the absorption of the cisplatin active ingredient and will be applied prior to patch application.

Intervention Type: DRUG

Other Intervention Names

Cisplatin; Cisplatin

Eligibility Criteria

Inclusion Criteria

In order to be eligible to participate in the study, an individual must meet all of the following criteria:

• Diagnosis Arm 1: Pathologically proven and clinically confirmed Tis/CIS of the lip or oral cavity Arm 2: Pathologically proven and clinically confirmed T1-T3, Nx,M0 of the lip or oral cavity

Criteria for Inclusion for both ARM 1 & ARM 2:

1. Tumors for which the cytological and architectural changes upon histopathological assessment warrant surgical intervention

2. Adult subjects, men and women, defined by age ≥18 years at the time of screening.

3. Tumor must be accessible, with no evidence of infection or active bleeding.

4. Tumor is amenable to surgical resection within 8 weeks of screening visit (Visit 0).

5. Clinically and/or radiologically measurable tumor.

6. Eastern Collaborative Oncology Group Performance Status of ≤2.

7. Male and female subjects of childbearing potential must agree to use 2 methods of effective contraception from screening and for at least 30 days after the final dose of investigational product. Appropriate birth control is defined as barrier methods with spermicides, oral or parenteral contraceptives and/or intrauterine devices, or naturally or surgically sterile (with documentation in the subject's medical records). Postmenopausal women are defined as presenting at least 12 months' natural spontaneous amenorrhea, or at least 6 weeks following surgical menopause (bilateral oophorectomy). Females of childbearing potential must be non-lactating and have a negative serum hCG within 14 days of treatment initiation.

8. Absence of any serious underlying medical conditions which could impair the ability of the subject to participate in the study.

9. Have a life expectancy of ≥3 months.

10. Willing and able to provide written informed consent.

11. Able to return to study site for treatment and follow-up visits as defined in the Protocol.

Criteria for Exclusion for both ARM 1 and ARM 2 (unless specified):

An individual who meets any of the following criteria will be excluded from participation in the study:

1. Subjects that are not eligible for surgery as SOC.

2. Patients with a prior history of invasive squamous cell carcinoma (Arm 1 only)

3. Tumors involving the marginal gingiva (Arm 1 only)

4. Squamous cell carcinoma (SCC) of the oral cavity that received previous radiotherapy.(Arm 1 only)

5. Systemic chemotherapy for the treatment of SCC of the head and neck less than 2 years prior to Screening (Arm 1 only)

6. Concurrent documented malignancy, with the exception of localized SCCs and basal cell carcinoma of the skin Exposure to any investigational agent within 3 months prior to Screening

7. Known allergy or hypersensitivity to platinum-containing agents, or known intolerance to a prior platinum- containing agent, or to any of the excipients, which, in the judgement of the physician will preclude re- exposure to platinum-containing agent

8. Active, uncontrolled infection requiring systemic therapy, such as but not limited to HIV, Syphilis, Hepatitis B, or Hepatitis C

9. Uncontrolled intercurrent illness that would risk subject safety, interfere with the objectives of the Protocol, or limit subject compliance with study requirements, as determined by the Investigator

10. Known or suspected pregnancy, planned pregnancy, or lactation

11. Any medical or psychiatric condition that may compromise the ability to give written informed consent

12. Known diagnosis of oral submucous fibrosis (Arm 1 only)

13. Known diagnosis of trismus (Arm 1 only)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 100 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: collaborator

Privo Technologies

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

City of Hope National Medical Center

Duarte, California, United States

Site Status: RECRUITING

Miami Cancer Institute

Miami, Florida, United States

Site Status: RECRUITING

The University of Chicago

Chicago, Illinois, United States

Site Status: RECRUITING

The Cleveland Clinic Foundation

Cleveland, Ohio, United States

Site Status: RECRUITING

Countries

United States

Facility Contacts

Krupal Patel, MD Assistant Clinical ProfessorDivision of Head and Neck Surgery

Role: primary

kruppatel@coh.org

626-218-7100

Alessandra Villa, DDS Chief of oral medicine, oral oncology and dentistry at Miami C

Role: primary

alessandro.villa@baptisthealth.net

786-527-8151

Alexander Pearson, MD

Role: primary

apearson5@medicine.bsd.uchicago.edu

773-834-1604

Kyunghee Burkitt, MD Department of Hematology and Medical Oncology

Role: primary

burkitk@ccf.org

216-339-6492

Other Identifiers

CLN-004

Identifier Type: -

Identifier Source: org_study_id